GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.

@article{Bildik2015GnRHAL,
  title={GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.},
  author={Gamze Bildik and Nazli Akin and Filiz Senbabaoglu and Gizem Nur Sahin and Sercin Karahuseyinoglu and Umit Ince and Çağatay Taşkıran and Ugur Selek and Kayhan Yakın and Yılmaz Guzel and Cem Ayhan and Ebru Alper and Mustafa Çetiner and Başak Balaban and Nil Molinas Mandel and Tarık Esen and Akira Iwase and Bulent Urman and Ozgur Oktem},
  journal={Human reproduction},
  year={2015},
  volume={30 12},
  pages={
          2912-25
        }
}
STUDY QUESTION Is there any in vitro evidence for or against ovarian protection by co-administration of a GnRH agonist with chemotherapy in human? SUMMARY ANSWER The co-administration of GnRH agonist leuprolide acetate with cytotoxic chemotherapy agents does not preserve ovarian reserve in vitro. WHAT IS KNOWN ALREADY Randomized controlled trials of the co-administration of gonadotrophin-releasing hormone (GnRH) agonists with adjuvant chemotherapy to preserve ovarian function have shown… 
GnRH Analogues as a Co-Treatment to Therapy in Women of Reproductive Age with Cancer and Fertility Preservation
TLDR
GnRH analogues may be a valuable prophylactic agent against chemotherapeutic infertility by inhibiting rapid cellular turnover on growing follicles that contain types of cells unintentionally targeted during anti-cancer treatments during chemo-radiation treatments.
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review
TLDR
The mechanisms of GnRHa in the preservation of fertility in premenopausal cancer patient candidates to receive chemotherapy are summarized, highlighting the areas of doubt that require further investigation.
Both in vivo FSH depletion and follicular exposure to Gonadotrophin-releasing hormone analogues in vitro are not effective to prevent follicular depletion during chemotherapy in mice
TLDR
The findings demonstrate that ovarian damage occurred even in the absence of FSH, suggesting that inhibition of the pituitary-gonadal axis is not involved in ovarian protection during GnRH analogues treatment.
GnRH agonist for gonadal protection during chemotherapy.
TLDR
In this issue of Human Reproduction, Bildik et al. report an in vitro model to explore if there is molecular evidence for-or-against the role of GrRHa in the prevention of chemotherapy-induced ovarian damage and show that GnRHa does not affect these parameters.
Appraising the Biological Evidence for and Against the Utility of GnRHa for Preservation of Fertility in Patients With Cancer.
  • K. Oktay, G. Bedoschi
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
A small, overlooked, yet well-designed study by Waxman et al was the first randomized study to investigate the benefit of ovarian suppression in patients of both genders with lymphoma who received gonadotoxic chemotherapy, and found some evidence, however, that oocytes are capable of mounting a DNA damage response.
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells
TLDR
The data suggest that the protective mechanisms induced by GnR Ha is mediated by an anti-apoptotic effect on CC, and glutathione synthesis was decreased after GnRHa treatment both in CC and oocytes.
LH prevents cisplatin-induced apoptosis in oocytes and preserves female fertility in mouse
TLDR
In vivo administration to prepubertal female mice of a single dose of LH together with Cs inhibited the depletion of the primordial follicle reserve caused by the drug and preserved their fertility in reproductive age, preventing significant alteration in the number of pregnancy and of delivered pups.
Ovarian damage from chemotherapy and current approaches to its protection
TLDR
The different damaging effects of the most common chemotherapeutic compounds on the ovary, in particular, the ovarian follicles and the molecular pathways that lead to that damage are discussed and recently described fertility-protective agents with these damage pathways are discussed.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
Gonadatrophin Suppression to Prevent Chemotherapy-Induced Ovarian Damage: A Randomized Controlled Trial
TLDR
GnRH analogue cotreatment does not offer a significant protective effect on ovarian function in patients treated by cyclophosphamide-based chemotherapy and did not predict independently the odds of menstruating at 12 months.
Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain.
TLDR
The utility of GnRHa as a fertility preservation strategy remains uncertain, and use outside of a clinical trial generally not recommended.
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
TLDR
The use of triptorelin-induced temporary ovarian suppression during chemotherapy in premenopausal patients with early-stage breast cancer reduced the occurrence of chemotherapy-induced early menopause.
Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
TLDR
Premenopausal patients with breast cancer receiving goserelin simultaneously with modern neoadjuvant chemotherapy did not experience statistically significantly less amenorrhea 6 months after end of chemotherapy compared with those receiving chemotherapy alone.
Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
  • P. Munster, A. Moore, S. Minton
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
This prospective randomized trial evaluated the use of gonadotropin-releasing hormone (GnRH) analog triptorelin to preserve ovarian function in women treated with chemotherapy for early-stage breast cancer and found amenorrhea rates on triPTorelin were comparable to those seen in the control group.
A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve.
TLDR
The impact of cyclophosphamide on primordial follicle reserve in the human ovarian xenograft model is consistent with the clinical gonadotoxicity of this drug.
How do chemotherapeutic agents damage the ovary?
TLDR
It is likely that different chemotherapeutic drugs act through a range of mechanisms and on different target cells, and more research into the cellular mechanisms underpinning chemotherapy-induced follicle loss could lead to the generation of treatments specifically designed to prevent POF.
Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial
TLDR
There is some evidence of protective effect of goserelin on ovarian function in CMF treated women, and there was a statistically significant increase in the proportion of menstruating women 1 year after completed treatment compared to at 24 months of treatment, in contrast to all other treatment groups, who were unchanged or more often amenorrheic.
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
TLDR
The survival benefit of adjuvant chemotherapy in young women with operable hormone receptor–negative breast cancer is well known, but concern over becoming infertile may influence the choice of treatment.
...
...